In the vast ocean of financial markets, where giants often dominate the headlines, there lies a realm of opportunities waiting to be explored by those with a keen eye and an appetite for adventure. Welcome to the world of small cap stock bottom fishing, where the thrill of discovery meets the potential for substantial returns. Let's plunge into the world of five small-cap stocks, where the greatest catches often elude the casual observer but can be the stuff of legends for those who dare to explore.
--
ARB IOT Group Limited (NASDAQ: ARBB) - ARB IOT Group Limited specializes in comprehensive IoT solutions, covering everything from system design to project implementation. Our goal is to establish a prominent presence in the ASEAN IoT sector. We offer a diverse array of IoT systems and provide extensive services, including system integration and support. Our solutions encompass end-to-end deployment, from design and installation to testing, pre-commissioning, and commissioning of various IoT systems and devices. We also excel in automating systems, handling both wired and wireless installations, along with mechatronic work integration. In April, the company went public at $4 per share. In June, they made a groundbreaking partnership with Potboy Group, a rapidly growing retail operator in Malaysia, to introduce 'Pick-N-Go' machines at select MRT stations, revolutionizing retail and technology integration in the country. The initiative will roll out in two phases, with about 100 units across 18 MRT stations in the first phase and a target of 200 machines across 50 locations by year-end. The company plans to expand to high-traffic areas like airports, bus depots, universities, and hospitals, aiming for approximately RM1.0 billion in sales. We will keep a vigilant eye on this stock for upcoming company announcements and interactions, especially considering its recent drop below the $2 mark.
--
Clearmind Medicine Inc. (NASDAQ: CMND) - Clearmind is a biotech firm specializing in psychedelic pharmaceuticals. Their core mission is to create innovative therapeutics from psychedelics to address unmet health needs, such as alcohol use disorder. They aim to research, develop, and bring these compounds to market as regulated medicines, foods, or supplements. With a current intellectual property portfolio of fifteen patent families, Clearmind also seeks further patents and opportunities to expand its intellectual property holdings. The company recently completed its U.S.-only public offering, raising approximately US$2.25 million in gross proceeds, excluding placement agent fees and other expenses. The offering included 7,500,000 common shares and pre-funded warrants, along with 7,500,000 common warrants. These common warrants are immediately exercisable with an exercise price of US$0.30 (CAD$0.40) per common share, valid for five years from the issuance date. Additionally, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, is scheduled to participate in the 8th Annual Dawson James Conference on October 12th, 2023, in Jupiter, Florida. The company's management will engage in one-on-one meetings with qualified investors during the conference. Since the offering, the company's share price has declined to under $0.15 cents, prompting us to closely monitor the company for updates and potential price rebound.
--
Azitra Inc. (NYSE American: AZTR) - Azitra, Inc. is an early-stage clinical biopharmaceutical company specializing in precision dermatology treatments through the use of engineered proteins and topical live biotherapeutic products. The company has developed a unique platform featuring a proprietary microbial library containing distinctive bacterial strains, which can be evaluated for therapeutic potential and lead drug candidates. This platform is further enhanced by artificial intelligence and machine learning technology, enabling the analysis, prediction, and screening of the strain library for drug-like molecules. Azitra's primary focus centers on the development of genetically engineered strains of Staphylococcus epidermidis, regarded as an ideal candidate species for dermatological therapeutic engineering. The company went public in June at $5 per share. They recently announced that COO Travis Whitfill will provide an overview at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, with one-on-one meetings with management during the event. Regarding their product candidates, they are currently focused on ATR-04, a genetically modified S. epidermidis strain for treating skin issues in cancer patients on EGFRi therapy. They plan to submit an IND for a Phase 1b clinical trial by the end of 2023, with Phase 1b expected in H1 2024. They've also received FDA approval to proceed with a Phase 1b trial for ATR-12 in Netherton syndrome patients, set to begin in H2 2023, with initial results in H1 2024. The company is collaborating with Bayer Consumer Care AG on bacterial microbes. Bayer holds the option to license the patent rights to selected strains. Bayer invested $8 million in the company's Series B preferred stock in December 2020. We'll closely monitor this company for updates and potential price movements.
--
Intelligent Bio Solutions Inc. (NASDAQ: INBS) - Intelligent Bio Solutions Inc. is a medical tech company pioneering rapid, non-invasive testing with its Intelligent Fingerprinting Drug Screening System. This system utilizes fingerprint sweat analysis for quick, hygienic, and cost-effective drug screening, benefiting industries like construction, manufacturing, transportation, and drug treatment. With results in under ten minutes, it targets drugs such as opioids, cocaine, methamphetamine, and cannabis. Moreover, INBS's biosensor platform has broad potential, offering over 130 testing indications, from glucose to immunological conditions and infectious diseases. The company recently closed a public offering, generating around $4.378 million before deducting fees and expenses. The offering included the underwriter's over-allotment option. Units were priced at $0.55 each. Furthermore, they've adopted their Intelligent Fingerprinting Drug Screening System with VKVP Haulage, and have completed 25,000 tests with Auctus Management Group. We'll closely watch this stock for signs of a rebound.
--
Lion Group Holding Ltd. (NASDAQ: LGHL) - Lion Group Holding LTD. operates a comprehensive trading platform offering Total Return Service (TRS) Trading, Contract-for-Difference (CFD) trading, Insurance Brokerage, and Futures and Securities Brokerage services. They also have a skilled SPAC sponsorship team to assist private companies in their listing process and enhance Lion's own value. The company recently announced the launch of "Phoenix," an advanced AI-driven trading algorithm service. This innovation strengthens the company's product portfolio and is poised to boost its growth. Phoenix stands out for its industry-leading AI technology and potential to increase revenue. Given the stock's recent dip below $1 and a modest float of under 1 million shares, we'll be vigilant for updates, consolidation, and potential recovery.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.
CONTACT: CONTACT: https://bigtimepennystocks.com/
Editor: mail@bigtimepennystocks.com
.
ARB IOT GROUP LIMITED 
